Etrasimod Results Justify Pfizer’s Leap Of Faith In Arena Buyout
Big Pharma Executed $6.7bn Deal Without Seeing Phase III Data
Detailed data presented at Digestive Disease Week show competitive efficacy in ulcerative colitis and a potential best-in-class safety profile for the S1P receptor modulator Pfizer acquired earlier this year.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: etrasimod comes through for Pfizer; PTC confident on gene therapy; could CAR-Ts roll into the community setting; the attractions of Boston for Korean bioventures; and Ukraine war may claim Sputnik casualties.
The company is looking to refuel its immunology & inflammation portfolio as Xeljanz safety takes a toll and the franchise approaches loss of exclusivity.
Blockbusters like Stelara, Eliquis, Prolia and Ibrance are poised to lose US exclusivity over the next five years; pressure is mounting for industry to replenish the portfolio with the next high-growth brands.